Agenus Inc income statement

In fiscal 2025, Agenus Inc reported revenue of $114m, up 10.4% on the year before, operating income of −$20.2m (a -17.7% margin) and net income of −$101,000, or $0.00 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Agenus Inc: income statement, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2011Dec 2011	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	3	3	3	16	3	7	25	23	43	37	150	88	296	98	156	103	114	133
Cost of revenue	—	—	—	—	—	—	—	—	—	—	—	2	3	11	3	0	1	1
Gross profit	—	—	—	—	—	—	—	—	—	—	—	86	292	87	153	103	113	132
Research and development	17	13	11	11	13	22	70	95	116	125	168	143	179	187	235	156	79	58
General and administrative	14	12	11	11	14	21	28	33	34	37	46	59	76	81	79	72	54	38
Operating income	−28	−22	−19	−7	−25	−43	−81	−107	−104	−124	−70	−117	26	−179	−160	−120	−20	36
Interest expense	5	5	4	5	2	1	4	19	31	—	—	—	—	64	104	120	56	59
Provision for credit losses	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0	0	0	—
Income before tax	—	—	—	—	−30	−42	−93	−127	−121	—	—	—	—	—	−257	−232	−3	—
Income tax	—	—	0	0	0	0	−5	0	0	0	0	0	0	0	0	0	0	—
Net income	−30	−22	−23	−11	−30	−42	−88	−127	−121	−160	−108	−181	−24	−220	−246	−227	−0	92
Diluted EPS	−$1.18	−$0.70	−$0.60	−$0.26	−$0.56	−$0.71	−$1.13	−$1.46	−$1.23	−$1.44	−$0.80	−$1.05	−$0.11	−$15.64	−$13.75	−$10.59	$0.00	$2.52
Diluted shares (average)	—	—	—	—	60m	60m	78m	87m	98m	111m	135m	173m	229m	14m	18m	21m	30m	36m
EBITDA	−24	−18	−17	−5	−24	−42	−79	−103	−98	−118	−63	−110	33	−172	−146	−107	−10	41

US$ millions unless shown otherwise. Fiscal quarters.

Agenus Inc: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	25	27	24	26	30	34	34	35
Cost of revenue	0	0	0	0	1	0	0	0
Gross profit	25	27	24	25	30	34	34	35
Research and development	41	34	22	27	24	8	12	15
General and administrative	17	21	16	16	11	12	7	8
Operating income	−32	−26	−13	−17	−5	14	15	11
Interest expense	37	21	13	13	13	16	15	15
Net income	−66	−46	−25	−28	64	−11	39	−1
Diluted EPS	−$3.08	−$1.94	−$1.03	−$1.00	$1.94	−$0.37	$1.02	−$0.01
EBITDA	−28	−23	−10	−14	−2	15	16	12

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AGEN vs MESO AGEN vs KPTI AGEN vs RCUS AGEN vs BEAM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Agenus Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Agenus Inc.